Management of extensively drug-resistant Acinetobacter baumannii bacteremia with cefiderocol and sulbactam-durlobactam: a case report
Related Experiment Video
Updated: Jan 11, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
E J Kim1, M Snyder2, K Macaluso2
1Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Background:
Extensively drug-resistant (XDR) Acinetobacter baumannii presents an urgent threat to public health due to its significant morbidity and mortality, with limited evidence-based treatment options. Recent drug developments of cefiderocol (FDC) and sulbactam-durlobactam (SUD) provide novel treatment options for XDR A. baumannii.
Case Summary:
We present the case of a patient with XDR A. baumannii bacteremia following a prolonged hospital course for gangrenous cholecystitis and hospital-acquired bacterial pneumonia. He completed a 14-day course of FDC and SUD with clinical resolution and was discharged home.
Conclusion:
This case demonstrates the potential efficacy of FDC combined with SUD in treating XDR A. baumannii bacteremia, highlighting the need for further research into combination therapy regimens for XDR A. baumannii.
More Related Videos
05:06Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Development of Antibiotic Resistance